Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Predictive Oncology ( (POAI) ).
Predictive Oncology has issued and sold shares to an accredited investor under a Purchase Agreement. This transaction was conducted in reliance on exemptions from registration requirements under the Securities Act, indicating a strategic financial maneuver to potentially enhance the company’s capital structure.
The most recent analyst rating on (POAI) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.
Spark’s Take on POAI Stock
According to Spark, TipRanks’ AI Analyst, POAI is a Underperform.
The overall stock score is heavily impacted by significant financial challenges, including declining revenues and negative profit margins. The technical analysis indicates a bearish trend, and the valuation reflects ongoing losses with no dividend yield. Additionally, the risk of delisting due to Nasdaq non-compliance further pressures the stock’s outlook.
To see Spark’s full report on POAI stock, click here.
More about Predictive Oncology
Average Trading Volume: 161,329
Technical Sentiment Signal: Strong Sell
Current Market Cap: $9.53M
See more insights into POAI stock on TipRanks’ Stock Analysis page.